Image-guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake.
Qianlu YangSisi DengHeike PreibschTim-Colin SchadeAndré KochGeorgy BerezhnoyLaimdota ZizmareAnna FischerBrigitte GückelAnnette StaeblerAndreas D HartkopfBernd J PichlerChristian Peter la FougèreMarkus HahnIrina BonzheimKonstantin NikolaouChristoph TrautweinPublished in: Clinical and translational medicine (2024)
F]FDG tracer uptake, transcriptome and tumour metabolites like acetate and serine facilitate the search for new candidates for metabolic tracers and permit distinguishing luminal A and B. This knowledge may help to differentiate subtypes preclinically or to provide patients guide for neoadjuvant therapy and optimised surgical protocols based on individual tumour metabolism.
Keyphrases
- single cell
- end stage renal disease
- pet imaging
- positron emission tomography
- rna seq
- endothelial cells
- newly diagnosed
- chronic kidney disease
- ejection fraction
- genome wide
- healthcare
- gene expression
- prognostic factors
- ms ms
- mass spectrometry
- peritoneal dialysis
- rectal cancer
- computed tomography
- lymph node
- metabolic syndrome
- locally advanced
- blood glucose
- patient reported outcomes
- mesenchymal stem cells
- adipose tissue
- type diabetes
- protein kinase